Ilya Pharma have been granted a preIND meeting with the FDA related to the development of ILP100-Oral
The company have requested and been granted a preIND Type B meeting with the FDA regarding its developments of ILP100-Oral for the planned clinical development in cancer patients with colitis as a result of their cancer treatment. Today 30-40% of cancer patients receiving treatment with immune checkpoint inhibitors (ICIs) have to discontinue the treatment due to colitis. The Company will report the outcome of the meeting and any next steps forward.